Cantor Fitzgerald Analysts Give Integra Lifesciences (IART) a $54.00 Price Target

Share on StockTwits

Cantor Fitzgerald set a $54.00 target price on Integra Lifesciences (NASDAQ:IART) in a research note issued to investors on Tuesday morning. The brokerage currently has a hold rating on the life sciences company’s stock.

IART has been the subject of a number of other reports. Oppenheimer restated a buy rating and set a $70.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, October 31st. JMP Securities reduced their price objective on shares of Integra Lifesciences from $66.00 to $62.00 and set a market outperform rating for the company in a research note on Friday, November 2nd. UBS Group initiated coverage on shares of Integra Lifesciences in a report on Tuesday, November 27th. They issued a neutral rating and a $58.00 target price on the stock. Zacks Investment Research cut shares of Integra Lifesciences from a hold rating to a sell rating in a report on Tuesday, September 25th. Finally, Citigroup dropped their target price on shares of Integra Lifesciences from $66.00 to $60.00 and set a neutral rating on the stock in a report on Friday, November 2nd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company. Integra Lifesciences has a consensus rating of Hold and an average target price of $62.00.

NASDAQ IART traded down $0.35 on Tuesday, reaching $45.15. The company had a trading volume of 15,357 shares, compared to its average volume of 590,726. The firm has a market cap of $3.93 billion, a PE ratio of 23.23, a PEG ratio of 1.29 and a beta of 0.93. The company has a current ratio of 3.20, a quick ratio of 2.08 and a debt-to-equity ratio of 1.04. Integra Lifesciences has a 1-year low of $42.14 and a 1-year high of $67.50.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.59. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The company had revenue of $365.85 million during the quarter, compared to the consensus estimate of $367.89 million. During the same period in the prior year, the business posted $0.45 EPS. The company’s quarterly revenue was up 31.2% on a year-over-year basis. Equities research analysts forecast that Integra Lifesciences will post 2.39 EPS for the current year.

In related news, Director Barbara B. Hill purchased 3,705 shares of the stock in a transaction on Monday, November 5th. The shares were purchased at an average cost of $53.90 per share, with a total value of $199,699.50. Following the acquisition, the director now directly owns 63,381 shares in the company, valued at $3,416,235.90. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Richard E. Caruso sold 46,676 shares of the stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the completion of the transaction, the insider now directly owns 134,134 shares in the company, valued at $8,475,927.46. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Retirement Systems of Alabama raised its holdings in Integra Lifesciences by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 91,666 shares of the life sciences company’s stock valued at $4,134,000 after acquiring an additional 352 shares during the period. Commonwealth Equity Services LLC grew its position in shares of Integra Lifesciences by 8.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 11,913 shares of the life sciences company’s stock worth $784,000 after purchasing an additional 965 shares in the last quarter. First National Bank of Omaha grew its position in shares of Integra Lifesciences by 2.8% during the 3rd quarter. First National Bank of Omaha now owns 39,980 shares of the life sciences company’s stock worth $2,633,000 after purchasing an additional 1,076 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Integra Lifesciences by 20.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,904 shares of the life sciences company’s stock worth $455,000 after purchasing an additional 1,156 shares in the last quarter. Finally, Arizona State Retirement System grew its position in shares of Integra Lifesciences by 2.4% during the 3rd quarter. Arizona State Retirement System now owns 50,172 shares of the life sciences company’s stock worth $3,305,000 after purchasing an additional 1,196 shares in the last quarter. 85.90% of the stock is currently owned by hedge funds and other institutional investors.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Further Reading: Day Trading – Risk Worth the Reward?

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply